Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
NAFLD (non-alcoholic fatty liver disease) encompasses the spectrum of fatty liver disease in insulin-resistant individuals who often display T2DM (Type 2 diabetes mellitus) and obesity. The present review highlights the pathophysiological basis and clinical evidence for a possible causal linkage between NAFLD and CVD (cardiovascular disease). The role of traditional and non-traditional CVD risk factors in the pathophysiology of NAFLD is considered in the first part of the review, with the basic science shared by atherogenesis and hepatic steatogenesis discussed in depth in the second part. In conclusion, NAFLD is not an innocent bystander, but a major player in the development and progression of CVD. NAFLD and CVD also share similar molecular mechanisms and targeted treatment strategies. On the research side, studies should focus on interventions aimed at restoring energy homoeostasis in lipotoxic tissues and at improving hepatic (micro)vascular blood supply.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Barroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Minireview: Adiposity, Inflammation, and Atherogenesis
Lyon, C. J., Law, R. E., & Hsueh, W. A. (2003) · Endocrinology · doi:10.1210/en.2003-0285 · Cited by 761
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoelson, S. E., & Shulman, G. I. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214955 · Cited by 557
Habitual Physical Activity Is Associated With Intrahepatic Fat Content in Humans
Perseghin, G., Lattuada, G., De Cobelli, F., Ragogna, F., Ntali, G., Esposito, A., Belloni, E., Canu, T., Terruzzi, I., Scifo, P., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2032 · Cited by 320
Schmitz-Peiffer, C., Browne, C. L., Oakes, N. D., Watkinson, A., Chisholm, D. J., Kraegen, E. W., & Biden, T. J. (1997) · Diabetes · doi:10.2337/diab.46.2.169 · Cited by 314
Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes
Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000160198.05416.72 · Cited by 293
Church, T. S., Kuk, J. L., Ross, R., Priest, E. L., Biltoff, E., & Blair, S. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.019 · Cited by 268
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00010 · Cited by 257
Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity
De Taeye, B. M., Novitskaya, T., McGuinness, O. P., Gleaves, L., Medda, M., Covington, J. W., & Vaughan, D. E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00194.2007 · Cited by 208
Intramyocellular Lipid Content in Human Skeletal Muscle
Schrauwen‐Hinderling, V. B., Hesselink, M. K. C., Schrauwen, P., & Kooi, M. E. (2006) · Obesity · doi:10.1038/oby.2006.47 · Cited by 202
Regular Physical Activity and Coronary Risk Factors in Japanese Men
Hsieh, S. D., Yoshinaga, H., Muto, T., & Sakurai, Y. (1998) · Circulation · doi:10.1161/01.cir.97.7.661 · Cited by 114
Cardiovascular risk in Cushing’s syndrome
Arnaldi, G., Mancini, T., Polenta, B., & Boscaro, M. (2004) · Pituitary · doi:10.1007/s11102-005-1172-7 · Cited by 103
Cited by
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 287
Nonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 270
A simple index of lipid overaccumulation is a good marker of liver steatosis
Bedogni, G., Kahn, H. S., Bellentani, S., & Tiribelli, C. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-98 · Cited by 253
Liver ATP Synthesis Is Lower and Relates to Insulin Sensitivity in Patients With Type 2 Diabetes
Schmid, A. I., Szendroedi, J., Chmelik, M., Krššák, M., Moser, E., & Roden, M. (2011) · Diabetes Care · doi:10.2337/dc10-1076 · Cited by 212
Abnormal Hepatic Energy Homeostasis in Type 2 Diabetes†
Szendroedi, J., Chmelik, M., Schmid, A. I., Nowotny, P., Brehm, A., Krssak, M., Moser, E., & Roden, M. (2009) · Hepatology · doi:10.1002/hep.23093 · Cited by 204
Metadata
- Authors
- Loria, P., Lonardo, A., & Targher, G.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2008-06-02
- Volume
- 115
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2013002822
- Cited by
- 72
- References
- 22
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.